Literature DB >> 2842694

A naturally immunogenic virion-associated protein specific for HIV-2 and SIV.

X F Yu1, S Ito, M Essex, T H Lee.   

Abstract

The genomic organization of HIV-1 and the family of HIV-2 and SIV viruses is similar. However, there is an open reading frame, orf-x, that is present in HIV-2 and SIV, but not in HIV-1. The extent of protein sequence conservation in orf-x between HIV-2ROD and SIVMAC suggests that this open reading frame encodes a gene that may be important for infectivity or replication. Here, we show that the orf-x products of SIVMAC and HIV-2SBL-6669 are virion-associated and that the introduction of a premature stop codon into orf-x, did not abrogate virus infectivity and replication in vitro. Antibody reactivity to the orf-x product was detected in 35 of 42 HIV-2 positive serum samples and 11 of 52 SIV seropositive monkeys. No such antibodies were detected in HIV-1 positive donors, blood donors seronegative for both HIV-2 and HIV-1, or SIV seronegative monkeys. This suggests that orf-x is dispensable for in vitro replication of SIVMAC and that the orf-x gene product of HIV-2 or its antibody can be used to distinguish HIV-2 from HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842694     DOI: 10.1038/335262a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx.

Authors:  Efrem S Lim; Oliver I Fregoso; Connor O McCoy; Frederick A Matsen; Harmit S Malik; Michael Emerman
Journal:  Cell Host Microbe       Date:  2012-01-26       Impact factor: 21.023

3.  Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.

Authors:  W R Lee; X F Yu; W J Syu; M Essex; T H Lee
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

4.  A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpx-mediated SAMHD1 degradation.

Authors:  Wei Wei; Haoran Guo; Xianjun Liu; Hong Zhang; Lei Qian; Kun Luo; Richard B Markham; Xiao-Fang Yu
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

5.  Construction and characterization of an infectious DNA clone and of mutants of simian immunodeficiency virus isolated from the African green monkey.

Authors:  R Shibata; T Miura; M Hayami; H Sakai; K Ogawa; T Kiyomasu; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages.

Authors:  Mikako Fujita; Masami Otsuka; Masami Miyoshi; Boonruang Khamsri; Masako Nomaguchi; Akio Adachi
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

7.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.

Authors:  C Lavallée; X J Yao; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.